Register for streaming realtime charts, analysis tools, and prices.
Period:
Draw Mode:
| Volume | 416 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| PaxMedica Inc | PXMD | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 0.716 | 06:30:33 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 0.716 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 21 | 416 | - | 0.372 - 29.75 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 06:37:45 | 1 | $ 0.7059 | USD |
PaxMedica Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 5.33M | 7.41M | - | 0 | -18.29M | -2.47 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
PaxMedica News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical PXMD Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.69 | 0.8888 | 0.6018 | 0.7754463 | 1,119,213 | 0.026 | 3.77% |
| 1 Month | 0.5026 | 1.189 | 0.4011 | 0.7996559 | 7,234,055 | 0.2134 | 42.46% |
| 3 Months | 0.499 | 1.189 | 0.372 | 0.7827335 | 2,582,719 | 0.217 | 43.49% |
| 6 Months | 3.621 | 10.26 | 0.372 | 2.06 | 2,989,528 | -2.91 | -80.23% |
| 1 Year | 26.86 | 29.75 | 0.372 | 3.89 | 1,817,963 | -26.14 | -97.33% |
| 3 Years | 110.50 | 178.16 | 0.372 | 26.65 | 1,862,105 | -109.78 | -99.35% |
| 5 Years | 110.50 | 178.16 | 0.372 | 26.65 | 1,862,105 | -109.78 | -99.35% |
PaxMedica Description
| PaxMedica Inc an early clinical stage biopharmaceutical company focusing on the development of anti-purinergic therapies (or APT), for the treatment of neurodevelopmental disorders, including autism spectrum disorder (or ASD), and Fragile X syndrome tremor-ataxia (or FXTAS). It focuses on the development and testing of its lead program, PAX-101, an intravenous formulation of suramin, in the treatment of ASD and FXTAS. It is also focused on the treatment of Human African Trypanosomiasis (or HAT). Its candidate PAX-102, proprietary intranasal formulation of suramin, as well as other new chemical entities that are more targeted and highly selective antagonists of particular purinergic receptor subtypes. |
